ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Although non-steroidal anti-inflammatory drugs (NSAIDs) effectively relieve the pain and inflammation of osteoarthritis (OA), there remain suspicions that some, at least, may hinder the organised regrowth of cartilage. Recentin vivoresearch reviewed at the 15th Annual Meeting of the British Society for Rheumatology [Brighton, UK; April 1998] during a symposium entitled ‘Current concepts in arthritis: reviewing the evidence’, suggests that not all NSAIDs are equivalent in this respect.*Aceclofenac has recently been shown to increase cartilage synthesis in chondrocytes cultured from patients with OA and rheumatoid arthritis (RA), but not in those from controls. Some NSAIDs exert an inhibitory effect on cartilage synthesis which can be associated with clinical deterioration, while others are neutral with respect to cartilage formation. The balance between efficacy and tolerability has always been problematic for NSAIDs, particularly as many patients who take these drugs for OA are elderly. The results of a meta-analysis focusing on patient compliance, which were also shown to delegates at the congress, revealed a clear and significant advantage for aceclofenac in terms of compliance and tolerability in patients with OA and RA.

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Lymphoma is considered a prime target for monoclonal antibody therapy, since it can easily be targeted via the ubiquitous B-cell CD20 antigen. Rituximab [‘Rituxan’; Genentech, IDEC Pharmaceuticals] is the best known of the anti-CD20 antibodies currently available for the treatment of relapsed or refractory low-grade or follicular CD20-positive B-cell non-Hodgkin's lymphoma (NHL). However, only about half of the patients enrolled in pre-approval clinical studies responded to rituximab therapy, with only about 6% of recipients achieving complete remissions. Researchers have been looking for ways to boost the therapeutic efficacy of antibody therapy. Combination protocols with anti-CD20 antibodies and standard chemotherapy or radiotherapy are producing remission rates approaching 100% in patients with lymphoma, according to studies presented at the 11th International Conference on Monoclonal Antibodies for Cancer [California, US; March 1998].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS